This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Howell, S. J. Articles by Shalet, S. M. Search for Related Content PubMed PubMed Citation Articles by Howell, S. J. Articles by Shalet, S. M. Social Bookmarking                            What's this?

Testicular Function After Cytotoxic Chemotherapy: Evidence of Leydig Cell Insufficiency

From the Departments of Endocrinology, Medical Oncology, and Statistics, Christie Hospital National Health Service Trust, Withington, Manchester, United Kingdom.

Address reprint requests to S.M. Shalet, MD, Department of Endocrinology, Christie Hospital National Health Service Trust, Withington, Manchester, M20 4BX United Kingdom; email mmassey{at}picr.man.ac.uk

PURPOSE: To evaluate testicular function in men after treatment with cytotoxic chemotherapy.

PATIENTS AND METHODS: We measured testosterone, sex hormone–binding globulin (SHBG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels in 209 men after treatment with mechlorethamine, vinblastine, procarbazine, and prednisone, hybrid chemotherapy, or high-dose chemotherapy and in 54 healthy age-matched controls.

RESULTS: The mean age of the patients was 38 years (range, 19 to 68 years), and all patients had received chemotherapy between 1 and 22 years previously. Patients had significantly higher mean LH (7.9 v 4.1 IU/L; P < .0001) and FSH levels (18.8 v 3.1 IU/L; P < .0001) than controls. There was no significant difference in mean total testosterone level between the patients and controls, but there was a trend toward a lower mean testosterone/SHBG ratio in the patients (0.63 v 0.7; P = .08). Analysis of the hormonal parameters using a model that allowed for the effects of increasing age on testicular function showed evidence of significant recovery of gonadal function in the first 10 years after treatment. Fifty-two percent of patients had LH levels at or above the upper limit of normal, and 32% of patients had increased LH with testosterone levels in the lower half of the normal range, suggesting a degree of Leydig cell impairment.

CONCLUSION: In a significant proportion of men, there is good evidence of Leydig cell dysfunction after cytotoxic chemotherapy. The clinical significance of this Leydig cell dysfunction is not clear, but some of these men may benefit from testosterone replacement. Further studies are warranted.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. D. van Beek, M. Smit, M. M. van den Heuvel-Eibrink, F. H. de Jong, F. G. Hakvoort-Cammel, C. van den Bos, H. van den Berg, R. F.A. Weber, R. Pieters, and S. M.P.F. de Muinck Keizer-Schrama Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood Hum. Reprod., December 1, 2007; 22(12): 3215 - 3222. [Abstract] [Full Text] [PDF]

				D. M. Greenfield, S. J. Walters, R. E. Coleman, B. W. Hancock, R. Eastell, H. A. Davies, J. A. Snowden, L. Derogatis, S. M. Shalet, and R. J. M. Ross Prevalence and Consequences of Androgen Deficiency in Young Male Cancer Survivors in a Controlled Cross-Sectional Study J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3476 - 3482. [Abstract] [Full Text] [PDF]

				C.A.A. Silva and H.I. Brunner Review: Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 593 - 599. [Abstract] [PDF]

				J.R. Spermon, L. Ramos, A.M.M. Wetzels, C.G.J. Sweep, D.D.M. Braat, L.A.L.M. Kiemeney, and J.A. Witjes Sperm integrity pre- and post-chemotherapy in men with testicular germ cell cancer Hum. Reprod., July 1, 2006; 21(7): 1781 - 1786. [Abstract] [Full Text] [PDF]

				S. J. Howell and S. M. Shalet Spermatogenesis After Cancer Treatment: Damage and Recovery J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 12 - 17. [Abstract] [Full Text] [PDF]

				F. Dimeo, A. Schmittel, T. Fietz, S. Schwartz, P. Kohler, D. Boning, and E. Thiel Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment Ann. Onc., August 1, 2004; 15(8): 1237 - 1242. [Abstract] [Full Text] [PDF]

				D. J. Vaughn, G. A. Gignac, and A. T. Meadows Long-Term Medical Care of Testicular Cancer Survivors Ann Intern Med, March 19, 2002; 136(6): 463 - 470. [Abstract] [Full Text] [PDF]

				F. Zappa, T. Ward, J. Butler, E. Pedrinis, and A. McGown Overexpression of NAD(P)H:quinone oxidoreductase 1 in Human Reproductive System J. Histochem. Cytochem., September 1, 2001; 49(9): 1187 - 1188. [Abstract] [Full Text] [PDF]

				M. Schmiegelow, S. Lassen, H. S. Poulsen, K. Schmiegelow, H. Hertz, A.-M. Andersson, N. E. Skakkebak, and J. Muller Gonadal Status in Male Survivors following Childhood Brain Tumors J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2446 - 2452. [Abstract] [Full Text] [PDF]

				J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]

				R. Chatterjee, G.A. Haines, D.M.D. Perera, A. Goldstone, and I.D. Morris Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia Hum. Reprod., April 1, 2000; 15(4): 762 - 766. [Abstract] [Full Text] [PDF]